Overview
BPC-157 is a synthetic peptide derived from a sequence found in human gastric juice. It has been extensively studied in rodent models for its effects on healing, angiogenesis, and inflammation reduction. Though widely researched, it is not approved for human or veterinary use.
How it works
- Promotes angiogenesis
- Enhances nitric oxide production
- Upregulates VEGF signaling
- Increases GH receptor expression in tendon fibroblasts
- Stabilizes microvascular endothelium
- Accelerates fibroblast migration and F-actin formation
Dosing
Standard dose: 500 mcg SubQ or 1 mg orally, administered daily.
Caution In rodent studies, BPC-157 has been administered via intraperitoneal injection or oral routes, typically in the 10–20 μg/kg range. No standardized dosing exists for human application, and this compound is not approved by the FDA. All dosing references are based on animal models and for informational purposes only.
Cycling
- Daily injections for 4–6 weeks, then reassess healing response.
Side effects
- Common
- Anxiety and panic attacks (frequently user-reported)
- Nausea, fatigue, loss of appetite (user-reported)
- Insomnia and sleep disturbances (user-reported)
- Heart palpitations (user-reported)
- Warnings
- Depression and anhedonia (user-reported)
- Contamination risk: 30% of online peptides contain incorrect sequences; 65% exceed endotoxin thresholds (quality study)
Stacking & combinations
- With
TB-500
- Benefit
Enhanced connective tissue repair & muscle recovery
- With
KPV
- Benefit
Anti-inflammatory gut healing synergy
Lifestyle support
- Diet
High-quality protein intake (1.2g per pound body weight). Adequate micronutrients.
- Sleep
Consistent sleep of 8+ hours nightly. Stay well-hydrated to support tissue repair.
- Timing
Inject near injury site 1–2x daily. Can also be taken orally for gut issues.
- Exercise
Allow adequate recovery time between intense workouts (at least 1 rest day per week).
Research studies
Studies summarized for educational purposes only. Inclusion does not imply human use; referenced research was conducted in vitro, in animal models, or in regulated clinical trials.
Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
Chang CH, Tsai WC, Hsu YH, Pang JH. Molecules. 2014;19(11):19066–77. View source
This in vitro study examined the effect of BPC-157 on isolated rat Achilles tendon fibroblasts. The researchers reported a dose- and time-dependent upregulation of growth hormone receptor (GHR) expression at both the mRNA and protein level following BPC-157 exposure. The functional consequence — increased proliferation in the presence of growth hormone — was demonstrated via MTT proliferation assay and PCNA expression. Co-exposure to growth hormone activated the JAK2 signaling pathway downstream of the GHR, consistent with sensitization of tendon fibroblasts to anabolic signaling. The authors propose that BPC-157's reported effects on tendon repair in animal models may be partly mediated by this GHR-axis modulation.
Scientists studied how BPC-157 affects tendon cells in a laboratory dish. They found that BPC-157 increases the number of "docking sites" on tendon cells where the body's natural growth hormone can attach. With more docking sites available, tendon cells respond more strongly to growth hormone and grow faster. This may help explain why BPC-157 has been associated with tendon healing in animal studies — it appears to make tendon cells more responsive to a natural repair signal the body already produces.
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JH. J Mol Med (Berl). 2017;95(3):323–333. View source
This combined in vitro and in vivo study investigated the angiogenic mechanism of BPC-157. In human umbilical vein endothelial cells (HUVECs), BPC-157 increased capillary-like tube formation and was associated with upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) at both mRNA and protein levels. The peptide promoted VEGFR2 internalization — a step required for downstream activation — and triggered time-dependent phosphorylation of the VEGFR2-Akt-eNOS axis. In an animal model of leg ischemia, BPC-157 administration was associated with increased blood vessel density in the affected limb, consistent with the in vitro findings.
Researchers looked at how BPC-157 affects the cells that line blood vessels. They found that BPC-157 acts like a switch that tells these cells to grow new blood vessels. It does this by amplifying a signal pathway the body already uses for vessel growth. In a mouse model where blood flow to a leg was restricted, BPC-157 was associated with more new blood vessels forming. New blood vessels can deliver more oxygen and nutrients to injured tissue, which is one mechanism by which BPC-157 may support repair in animal studies.
Verified citations
3 · PubMed-checked- The promoting effect of pentadecapeptide BPC 157 on tendon healing.mechanismPMID 21030672
- BPC 157 and its role in accelerating musculoskeletal soft tissue healing.reviewPMID 30915550
- Multifunctionality and Possible Medical Application of the BPC 157 Peptide.reviewPMID 40005999
Reconstitution calculator
Subcutaneous (SQ)= 0.1 mL on a U-100 insulin syringe
Assumes a U-100 insulin syringe (100 units = 1 mL). This is a preparation aid, not a protocol · dose and route are the prescriber's decision. Refrigerate at 2–8°C after reconstitution. Use within 28 days.
Chemistry & PK
Bioavailability
Storage & handling
- Lyophilized
Store lyophilized powder at 2-8°C. Reconstituted solution remains stable at 2-8°C for up to 28 days. For oral use, dissolve in distilled water or saline solution just before administration.
- Reconstituted
Refrigerate at 2–8°C after reconstitution. Use within 28 days.
Used for
Cautions
Warning · BPC-157 crash risk in post-viral/ME-CFS
Post-viral/ME-CFS patients report crashing at standard dose; microdose 10–25%.
Legal / compounding
Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.